Compugen Rockets on $540M Bayer Immunotherapy Alliance

Boggs, Jennifer
August 2013
BioWorld International;8/7/2013, Vol. 18 Issue 32, p1
The article reports on the 44.5 percent increase in the share price of Compugen Ltd., a drug discovery company, following news of a possible 540-million-dollar deal with pharmaceutical company Bayer Healthcare to develop cancer immunotherapy drugs. Compugen began operating in the 1990s as a technology firm and became a full-fledged drug development company over the decade. Immune system proteins that have been discovered by Compugen are discussed.


Related Articles

  • COMPUGEN ACHIEVES MILESTONE IN COLLABORATION.  // Biotech Business;Aug2014, Vol. 27 Issue 8, p1 

    The article reports the achievement of Compugen Ltd., a drug discovery company, in the cancer immunotherapy collaboration with the firm Bayer Healthcare. Topics discussed include focus of the collaboration on the development and commercialization of therapeutic antibodies against two immune...

  • Halving Treatment Time. Breitstein, Jonna; N. T. M. // Pharmaceutical Executive;Nov2005, Vol. 25 Issue 11, p24 

    Reports on the collaboration between Bayer HealthCare AG and the Global Alliance for TB Drug Development. Significance of the collaboration for the improvement in the treatment of tuberculosis; Terms under the deal; Importance of the partnership to the pharmaceutical industry.

  • CLINIC ROUNDUP.  // BioWorld Today;5/20/2008, Vol. 19 Issue 98, p4 

    This section offers news briefs on the pharmaceutical industry in 2008. Bayer HealthCare AG and Nektar Therapeutics Inc of San Carlos, California have developed a drug-device combination called Amikacin Inhale which can treat pneumonia. Epeius Biotechnologies Corp. reported positive study...

  • 13 BAYER HEALTHCARE.  // Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p94 

    The article reports on the performance of Leverkusen, Germany-based Bayer Healthcare AG in 2010 and its prospects for growth in 2011.

  • I&I News Round-Up.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p15 

    The article offers news briefs related to pharmaceutical industries. Ranbaxy Laboratories Ltd. has been allowed by the Food and Drug Administration (FDA) to manufacture and market glycopyrrolate tablets USP 1mg and 2mg. An agreement to acquire Desonate and Neobenz micro from SkinMedica has been...

  • Chemical Efficiency Fragments. May, Mike // Drug Discovery & Development;Aug2007, Vol. 10 Issue 8, p12 

    The article offers world news briefs related to fragmentation in pharmaceutical firms. Evotec AG announces the development of its Innovation Center for Fragmented-Based Drug Discovery with EVOlution screening platform. A partnership is made between Bayer Healthcare AG and Prosteros Biostructures...

  • Zydus Cadila forms joint venture with Germany's Bayer Healthcare.  // Chemical Business;Feb2011, Vol. 25 Issue 2, p59 

    The article reports on the plan of drug manufacturer Zydus Cadila to form a 50:50 joint venture with German firm Bayer Healthcare to sell pharmaceutical products in India in 2011.

  • Dendreon: $356M Sale to Make Provenge, Gear Up for Launch. Hollingsworth, Catherine // BioWorld Today;12/14/2009, Vol. 20 Issue 239, p1 

    The article reports on the stock offering launched by Dendreon Corp. in an effort to raise approximately 356 million U.S. dollar. Dendreon priced its offering at 24.75 U.S. dollar per share of stock. The company plans to allocate proceeds from the stock offering to advanced the construction of...

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/30/2008, Vol. 19 Issue 20, p2 

    This section offers pharmaceutical industry news briefs as of January 30, 2008. Cell Therapeutics Inc. has approved a proposal to increase its number of authorized shares from 110 million to 210 million. Compugen Ltd. has reported results of in vivo validation studies of CGEN-855A and CGEN-855B,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics